Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/oxford-university-press/development-of-neutralizing-antibodies-against-sars-cov-2-using-a-high-0fLKzKbuk6
References (87)
-
Callaway (2021)
21Nature, 600
-
J Sevigny, P Chiao, T Bussière (2016)
The antibody aducanumab reduces Abeta plaques in Alzheimer's disease, 537
-
Walls (2020)
281Cell, 181
-
L Liu, S Iketani, Y Guo (2022)
An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses, 14
-
Callaway (2021)
197Nature, 600
-
TF Rogers, F Zhao, D Huang (2020)
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model, 369
-
M Hoffmann, P Arora, R Groß (2021)
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies, 184
-
Chi (2020)
650Science, 369
-
M Hoffmann, H Kleine-Weber, S Schroeder (2020)
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, 181
-
P Wang, MS Nair, L Liu (2021)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, 593
-
Wec (2020)
731Science, 369
-
L Liu, S Iketani, Y Guo (2022)
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2, 602
-
Wang (2020)
894Cell, 181
-
X Chi, R Yan, J Zhang (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2, 369
-
Rogers (2020)
956Science, 369
-
D Wrapp, N Wang, KS Corbett (2020)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, 367
-
Ju (2020)
115Nature, 584
-
Shi (2020)
120Nature, 584
-
Pinto (2020)
290Nature, 583
-
Dorp (2020)
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2Infect Genet Evol, 83
-
Wang (2021)
130Nature, 593
-
R Shi, C Shan, X Duan (2020)
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2, 584
-
B Korber, WM Fischer, S Gnanakaran (2020)
Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus, 182
-
Cao (2020)
73Cell, 182
-
Ying (2015)
8223Nat Commun, 6
-
SJ Zost, P Gilchuk, RE Chen (2020)
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein, 26
-
HP Yao, Y Sun, YQ Deng (2021)
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection, 31
-
OH Brekke, I Sandlie (2003)
Therapeutic antibodies for human diseases at the dawn of the twenty-first century, 2
-
Zhu (2021)
Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2Natl Sci Rev, 8
-
Wibmer (2021)
622Nat Med, 27
-
K Wang, Z Jia, L Bao (2022)
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants, 603
-
Lan (2020)
215Nature, 581
-
Liu (2022)
676Nature, 602
-
E Callaway, H Ledford (2021)
How bad is Omicron? What scientists know so far, 600
-
Y Wu, F Wang, C Shen (2020)
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, 368
-
Chan (2010)
301Nat Rev Immunol, 10
-
Zost (2020)
1422Nat Med, 26
-
J Hansen, A Baum, KE Pascal (2020)
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, 369
-
CK Wibmer, F Ayres, T Hermanus (2021)
SARS-CoV-2 501Y.V2 escapes neutralization by south African COVID-19 donor plasma, 27
-
E Callaway (2021)
Heavily mutated Omicron variant puts scientists on alert, 600
-
Hansen (2020)
1010Science, 369
-
Cele (2022)
654Nature, 602
-
Walker (2018)
297Nat Rev Immunol, 18
-
Q Wang, Y Zhang, L Wu (2020)
Structural and functional basis of SARS-CoV-2 entry by using human ACE2, 181
-
AM Clargo, AR Hudson, W Ndlovu (2014)
The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method, 6
-
E Cameroni, JE Bowen, LE Rosen (2022)
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift, 602
-
Gerard (2020)
715Nat Biotechnol, 38
-
D Planas, N Saunders, P Maes (2022)
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization, 602
-
JL Torres, G Ozorowski, E Andreano (2022)
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody, 119
-
A Gerard (2020)
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics, 38
-
Planas (2022)
671Nature, 602
-
Sevigny (2016)
50Nature, 537
-
D Planas, D Veyer, A Baidaliuk (2021)
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, 596
-
AC Chan, PJ Carter (2010)
Therapeutic antibodies for autoimmunity and inflammation, 10
-
Liu (2022)
eabn6859Sci Transl Med, 14
-
M Yuan, H Liu, NC Wu (2020)
Structural basis of a shared antibody response to SARS-CoV-2, 369
-
Y Cao, B Su, X Guo (2020)
Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells, 182
-
Yuan (2020)
1119Science, 369
-
Kreer (2020)
1663Cell, 182
-
Planas (2021)
276Nature, 596
-
B Ju, Q Zhang, J Ge (2020)
Human neutralizing antibodies elicited by SARS-CoV-2 infection, 584
-
Z Lv, YQ Deng, Q Ye (2020)
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody, 369
-
Wang (2022)
919Nature, 603
-
Korber (2020)
812Cell, 182
-
Westendorf (2022)
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsCell Rep, 39
-
Hoffmann (2020)
271Cell, 181
-
AC Walls, YJ Park, MA Tortorici (2020)
Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, 181
-
Torres (2022)
e2120976119Proc Natl Acad Sci U S A, 119
-
S Cele, L Jackson, DS Khoury (2022)
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization, 602
-
Clargo (2014)
143MAbs, 6
-
Liu (2020)
450Nature, 584
-
C Kreer, M Zehner, T Weber (2020)
Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients, 182
-
Wrapp (2020)
1260Science, 367
-
Lv (2020)
1505Science, 369
-
Yao (2021)
25Cell Res, 31
-
J Lan, J Ge, J Yu (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, 581
-
Y Cao, J Wang, F Jian (2022)
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies, 602
-
Wu (2020)
1274Science, 368
-
T Ying, P Prabakaran, L du (2015)
Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody, 6
-
Hoffmann (2021)
2384Cell, 184
-
D Pinto, YJ Park, M Beltramello (2020)
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, 583
-
Brekke (2003)
52Nat Rev Drug Discov, 2
-
Cameroni (2022)
664Nature, 602
-
AZ Wec, D Wrapp, AS Herbert (2020)
Broad neutralization of SARS-related viruses by human monoclonal antibodies, 369
-
Cao (2022)
657Nature, 602
-
LM Walker, DR Burton (2018)
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray, 18
-
L Liu, P Wang, MS Nair (2020)
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike, 584
- Publisher
- Oxford University Press
- Copyright
- © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
- eISSN
- 2516-4236
- DOI
- 10.1093/abt/tbad002
- Publisher site
- See Article on Publisher Site
Abstract
BackgroundRapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients.MethodsHere, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients’ B cells.ResultsUsing this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells.ConclusionThis simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.
Journal
Antibody Therapeutics – Oxford University Press
Published: Feb 17, 2023